

INmune Bio (NASDAQ:INMB) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided...
You can purchase shares of INmune Bio (NASDAQ:INMB) through any online brokerage.
Other companies in INmune Bio’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
INmune Bio has a consensus price target of $9.93.
The stock price for INmune Bio (NASDAQ: INMB) is $1.18 last updated November 5, 2026 at 6:06 PM EST.
There are no upcoming dividends for INmune Bio.
INmune Bio does not have any upcoming earnings scheduled.
There is no upcoming split for INmune Bio.
INmune Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease....